Revium Rx (RVRC) Liabilities and Shareholders Equity (2024 - 2026)

Revium Rx has disclosed Liabilities and Shareholders Equity across 3 years of filings, most recently posting $7.1 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $7.1 million; the TTM figure through Jun 2026 stood at $35.7 million (changed N/A YoY), while the FY2025 annual figure was $8.3 million, down 59.07% from the prior year.
• Liabilities and Shareholders Equity came in at $7.1 million for Q2 2026 at Revium Rx, down from $8.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $20.3 million in Q4 2024 to a low of $7.1 million in Q2 2026.
• Average Liabilities and Shareholders Equity over 3 years is $11.9 million, with a median of $8.3 million recorded in 2025.
• The largest YoY upside for Liabilities and Shareholders Equity was 59.07% in 2025 against a maximum downside of 59.07% in 2025.
• Over 3 years, Liabilities and Shareholders Equity stood at $20.3 million in 2024, then tumbled by 59.07% to $8.3 million in 2025, then retreated by 14.36% to $7.1 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $7.1 million in Q2 2026, $8.3 million in Q4 2025, and $20.3 million in Q4 2024.